Androgen receptor signaling in prostate cancer

Culig, Zoran; Santer, Frédéric R.

doi:10.1007/s10555-013-9474-0

Cited by 283Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentEstrogen and related hormone effects

Androgen receptor signaling in prostate cancer

Culig, Zoran, Santer, Frédéric R.·2014·Cancer and Metastasis Reviews

DOI 10.1007/s10555-013-9474-0

Open this paper in CoChat — free account

Abstract

The androgen receptor (AR), ligand-induced transcription factor, is expressed in primary prostate cancer and in metastases. AR regulates multiple cellular events, proliferation, apoptosis, migration, invasion, and differentiation. Its expression in prostate cancer cells is regulated by steroid and peptide hormones. AR downregulation by various compounds which are contained in fruits and vegetables is considered a chemopreventive strategy for prostate cancer. There is a bidirectional interaction between the AR and micro-RNA (miRNA) in prostate cancer; androgens may upregulate or downregulate the selected miRNA, whereas the AR itself is a target of miRNA. AR mutations have been discovered in prostate cancer, and their incidence may increase with tumor progression. AR mutations and increased expression of selected coactivators contribute to the acquisition of agonistic properties of anti-androgens. Expression of some of the coactivators is enhanced during androgen ablation. AR activity is regulated by peptides such as cytokines or growth factors which reduce the concentration of androgen required for maximal stimulation of the receptor. In prostate cancer, variant ARs which exhibit constitutive activity were detected. Novel therapies which interfere with intracrine synthesis of androgens or inhibit nuclear translocation of the AR have been introduced in the clinic.

Integrity signals

Registry

Crossref · 10.1007/s10555-013-9474-0

Cites

173 of 173 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

AR promotes transcriptional programs governing critical oncogenic phenotypes such as proliferation, migration and invasion.
“AR has been shown to promote transcriptional programs governing critical oncogenic phenotypes, such as proliferation, migration and invasion6.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [6]

1 retracted

Phosphorylation and activation of androgen receptor by Aurora-A.
Shu, S.-K., Liu, Q., Coppola, D., & Cheng, J. Q. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.121129 · Cited by 38 · see citing works
Retracted
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · see citing works
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796 · see citing works
International Journal of Oncology
(2026) · International Journal of Oncology · doi:10.3892/ijo · Cited by 2,332 · see citing works
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292 · see citing works
CLINICAL CANCER RESEARCH
Smithers, D. W. (1956) · The Lancet · doi:10.1016/s0140-6736(56)91184-9 · Cited by 1,796 · see citing works
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484 · see citing works
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Fizazi, K. S., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S. A., Vogelzang, N. J., Fred Saad, C., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,376 · see citing works
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,243 · see citing works
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M., Efstathiou, E., Rathkopf, D. E., Shelkey, J., Yu, E. Y., Alumkal, J. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60172-9 · Cited by 1,063 · see citing works
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L. (1999) · Nature Medicine · doi:10.1038/6495 · Cited by 980 · see citing works
A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgens
Veldscholte, J., Ris‐Stalpers, C., Kuiper, G. G. J. M., Jenster, G. W., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkmann, A. O., & Mulder, E. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80067-1 · Cited by 945 · see citing works
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
Čulig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., & Klocker, H. (1994) · PubMed · Cited by 938 · see citing works
Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903 · see citing works
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880 · see citing works
Androgen Levels Increase by Intratumoral <i>De novo</i> Steroidogenesis during Progression of Castration-Resistant Prostate Cancer
Locke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., Ettinger, S. L., Gleave, M. E., & Nelson, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5997 · Cited by 747 · see citing works
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., Chen, Y., Grillot, K., Bischoff, E. D., Cai, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3948 · Cited by 663 · see citing works
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines
Li, Y.-M., Chan, S.-C., Brand, L., Hwang, T., Silverstein, K., & Dehm, S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-3630 · Cited by 663 · see citing works
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., & Sawyers, C. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012443107 · Cited by 639 · see citing works
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Taplin, M., Bubley, G. J., Ko, Y., Small, E. J., Upton, M. P., Rajeshkumar, B. R., & Balk, S. P. (1999) · PubMed · Cited by 594 · see citing works
Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
Hu, R., Lu, C., Mostaghel, E. A., Yegnasubramanian, S., Gurel, M., Tannahill, C., Edwards, J., Isaacs, W. B., Nelson, P. S., Bluemn, E. G., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3892 · Cited by 585 · see citing works
Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
Mostaghel, E. A., Marck, B. T., Plymate, S. R., Vessella, R. L., Balk, S. P., Matsumoto, A. M., Nelson, P. S., & Montgomery, B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0728 · Cited by 583 · see citing works
Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization
Jenster, G., van der Korput, H. A. G. M., van Vroonhoven, C., van der Kwast, T. H., Trapman, J., & Brinkmann, A. O. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-10-1396 · Cited by 523 · cited 1× · see citing works
“Unlike other anti-androgens, it binds to the aminoterminal AF1 domain of AR, a region that is the major contributor of AR transcriptional activity [158].”
Background
Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.
Andersen, R. J., Mawji, N. R., Wang, J., Wang, G., Haile, S., Myung, J.-K., Watt, K., Tam, T., Yang, Y. C., Bañuelos, C. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.027 · Cited by 503 · see citing works
Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
Hörnberg, E., Ylitalo, E. B., Crnalic, S., Antti, H., Stattin, P. E., Widmark, A., Bergh, A. R. J., & Wikström, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019059 · Cited by 501 · see citing works
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone
Čulig, Z., Hobisch, A., Cronauer, M. V., Cato, A. C. B., Hittmair, A., Radmayr, C., Eberle, J., Bartsch, G., & Klocker, H. (1993) · Molecular Endocrinology · doi:10.1210/mend.7.12.8145761 · Cited by 440 · see citing works
Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
Cai, C., Chen, S., Ng, P., Bubley, G. J., Nelson, P. S., Mostaghel, E. A., Marck, B. T., Matsumoto, A. M., Simon, N. I., Wang, H., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0532 · Cited by 433 · see citing works
Activation of the human androgen receptor through a protein kinase A signaling pathway.
Nazareth, L. V., & Weigel, N. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19900 · Cited by 429 · see citing works
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara, T., Miyazaki, J., Araki, H., Yamaoka, M., Kanzaki, N., Kusaka, M., & Miyamoto, M. (2003) · PubMed · Cited by 425 · see citing works
Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells
Xing, N. (2001) · Carcinogenesis · doi:10.1093/carcin/22.3.409 · Cited by 416 · see citing works
miR-21: An Androgen Receptor–Regulated MicroRNA that Promotes Hormone-Dependent and Hormone-Independent Prostate Cancer Growth
Ribas, J., Ni, X., Haffner, M., Wentzel, E. A., Salmasi, A. H., Chowdhury, W. H., Kudrolli, T. A., Yegnasubramanian, S., Luo, J., Rodriguez, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1448 · Cited by 416 · see citing works
Expression of Transforming Growth Factor-β in the Rat Ventral Prostate during Castration-Induced Programmed Cell Death
Kyprianou, N., & Jt, I. (1989) · Molecular Endocrinology · doi:10.1210/mend-3-10-1515 · Cited by 413 · see citing works
Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system
Čulig, Z., Hoffmann, J., Erdel, M., Eder, I. E., Hobisch, A., Hittmair, A., Bartsch, G., Utermann, G., Schneider, M. R., Parczyk, K., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690684 · Cited by 410 · see citing works
Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
Danila, D. C., Morris, M. J., de Bono, J. S., Ryan, C. J., Denmeade, S. R., Smith, M. R., Taplin, M.-E., Bubley, G. J., Kheoh, T., Haqq, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9259 · Cited by 410 · see citing works
Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells.
Zegarra-Moro, O. L., Schmidt, L. J., Huang, H., & Tindall, D. J. (2002) · PubMed · Cited by 395 · see citing works
Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence.
Tilley, W. D., Buchanan, G., Hickey, T. E., & Bentel, J. M. (1996) · PubMed · Cited by 394 · see citing works
Androgen receptors in endocrine‐therapy‐resistant human prostate cancer
van der Kwast, T., Schalken, J. A., de Winter, J. A. R., van Vroonhoven, J. C. C., Mulder, E., Boersma, W. J. A., & Trapman, J. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910480206 · Cited by 387 · see citing works
Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways.
Ueda, T., Bruchovsky, N., & Sadar, M. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108255200 · Cited by 381 · see citing works
Alternatively spliced androgen receptor variants
Dehm, S. M., & Tindall, D. J. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0141 · Cited by 380 · see citing works
Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.021 · Cited by 364 · see citing works
Differential Effects on Growth, Cell Cycle Arrest, and Induction of Apoptosis by Resveratrol in Human Prostate Cancer Cell Lines
Hsieh, T., & WU, J. M. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4471 · Cited by 361 · see citing works
Androgen Deprivation Causes Epithelial–Mesenchymal Transition in the Prostate: Implications for Androgen-Deprivation Therapy
Sun, Y., Wang, B.-E., Leong, K. G., Peng, Y., Li, L., Jhunjhunwala, S., Chen, D., Seo, K., Modrusan, Z. D., Gao, W., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-3004 · Cited by 358 · see citing works
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Loriot, Y., Bianchini, D., Ileana, E., Sandhu, S. K., Patrikidou, A., Pezaro, C. J., Albiges, L. K., Attard, G., Fizazi, K. S., Bono, J. S. D., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt136 · Cited by 356 · see citing works
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
Zhu, M.-L., Horbinski, C. M., Garzotto, M., Qian, D. Z., Beer, T. M., & Kyprianou, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0585 · Cited by 352 · see citing works
Interleukin-6 Is an Autocrine Growth Factor in Human Prostate Cancer
Giri, D., Özen, M., & Ittmann, M. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63067-2 · Cited by 331 · see citing works
Phosphorylation of Akt (Ser473) is an Excellent Predictor of Poor Clinical Outcome in Prostate Cancer
Kreisberg, J. I., Malik, S. N., Prihoda, T. J., Bedolla, R. G., Troyer, D. A., Kreisberg, S. H., & Ghosh, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0272 · Cited by 324 · see citing works
Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells.
Ueda, T., Mawji, N. R., Bruchovsky, N., & Sadar, M. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203313200 · Cited by 311 · see citing works
Androgen receptor mutations in prostate cancer.
Barrack, E. R. (1996) · PubMed · Cited by 301 · see citing works
Interleukin-6: A candidate mediator of human prostate cancer morbidity
Twillie, D. A., Eisenberger, M. A., Carducci, M. A., Hseih, W.-S., Kim, W. Y., & Simons, J. W. (1995) · Urology · doi:10.1016/s0090-4295(99)80034-x · Cited by 286 · see citing works
Distant metastases from prostatic carcinoma express androgen receptor protein.
Hobisch, A., CULIG, Z., Radmayr, C., Bartsch, G., Klocker, H., & Hittmair, A. (1995) · PubMed · Cited by 283 · see citing works
Self-citation
Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation
Veldscholte, J., Berrevoets, C., Brinkmann, A. O., Grootegoed, J. A., & Mulder, E. (1992) · Biochemistry · doi:10.1021/bi00123a026 · Cited by 278 · see citing works
Systematic Analysis of MicroRNAs Targeting the Androgen Receptor in Prostate Cancer Cells
Östling, P., Leivonen, S., Aakula, A., Kohonen, P. J., Mäkelä, R., Hagman, Z., Edsjö, A., Kangaspeska, S., Edgren, H., Nicorici, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2421 · Cited by 271 · see citing works
Interleukin-6 regulation of prostate cancer cell growth.
Culig, Z., Steiner, H., Bartsch, G., & Hobisch, A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20477 · Cited by 269 · see citing works
Self-citation
Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line.
Tepper, C. G., Boucher, D. L., Ryan, P. E., Ma, A., Xia, L. P., Lee, L., Pretlow, T. G., & Kung, H.-J. (2002) · PubMed · Cited by 265 · see citing works
The Role of microRNA-221 and microRNA-222 in Androgen-Independent Prostate Cancer Cell Lines
Sun, T., Wang, Q., Balk, S. P., Brown, M. A., Lee, G. M., & Kantoff, P. W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4112 · Cited by 263 · see citing works
Cooperative Interactions between Androgen Receptor (AR) and Heat-Shock Protein 27 Facilitate AR Transcriptional Activity
Zoubeidi, A., Zardan, A., Beraldi, E., Fazli, L., Sowery, R. D., Rennie, P. S., Nelson, C. C., & Gleave, M. E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2057 · Cited by 256 · see citing works
MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1α/HIF-1β
Cao, P. D., Deng, Z., Wan, M., Huang, W., Cramer, S. D., Xu, J., Lei, M., & Sui, G. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-108 · Cited by 255 · see citing works
Pharmacology of novel steroidal inhibitors of cytochrome P45017 (17α-hydroxylase/C17–20 lyase)
Barrie, S. E., Potter, G. A., Goddard, P. M., Haynes, B. P., Dowsett, M., & Jarman, M. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90131-7 · Cited by 253 · see citing works
Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation.
Kokontis, J. M., Takakura, K., Hay, N., & Liao, S. (1994) · PubMed · Cited by 248 · see citing works
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens: Synthesis, in Vitro Biological Activity, Pharmacokinetics, and Antitumor Activity in the LAPC4 Human Prostate Cancer Xenograft Model
Handratta, V. D., Vasaitis, T. S., Njar, V. C. O., Gediya, L. K., Kataria, R. S., Chopra, P., Newman, D., Farquhar, R., Guo, Z., Qiu, Y., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040202w · Cited by 247 · see citing works
Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines
Santer, F. R., Höschele, P. P. S., Oh, S. J., Erb, H. H. H., Bouchal, J., Cavarretta, I. T. R., Parson, W., Meyers, D. J., Cole, P. A., & Čulig, Z. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0182 · Cited by 236 · see citing works
Self-citation
Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells
Yuan, T., Veeramani, S., & Lin, M. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0061 · Cited by 232 · see citing works
Expression of microRNA‐221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence
Spahn, M., Kneitz, S., Scholz, C. J., Stenger, N., Rüdiger, T., Ströbel, P., Riedmiller, H. N., & Kneitz, B. (2009) · International Journal of Cancer · doi:10.1002/ijc.24715 · Cited by 227 · see citing works
Hsp90 Regulates Androgen Receptor Hormone Binding Affinity in Vivo
Fang, Y., Fliss, A., Robins, D. M., & Caplan, A. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.45.28697 · Cited by 227 · see citing works
Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development
Halkidou, K., Gnanapragasam, V. J., Mehta, P. B., Logan, I. R., Brady, M. E., Cook, S., Leung, H. Y., Neal, D. E., & Robson, C. N. (2003) · Oncogene · doi:10.1038/sj.onc.1206342 · Cited by 214 · see citing works
MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma
Boll, K., Reiche, K., Kasack, K., Mörbt, N., Kretzschmar, A. K., Tomm, J. M., Verhaegh, G. W. C. T., Schalken, J. A., von Bergen�, M., Horn, F., et al. (2012) · Oncogene · doi:10.1038/onc.2012.55 · Cited by 214 · see citing works
Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells
Miyamoto, H., Yeh, S., Wilding, G., & Chang, C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7379 · Cited by 203 · see citing works
Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells.
Bakin, R. E., Gioeli, D. G., Sikes, R. A., Bissonette, E. A., & Weber, M. J. (2003) · PubMed · Cited by 201 · see citing works
Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer
Gregory, C. W., Fei, X., Ponguta, L. A., He, B., Bill, H. M., French, F. S., & Wilson, E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307649200 · Cited by 201 · see citing works
The RNA Helicase p68 Is a Novel Androgen Receptor Coactivator Involved in Splicing and Is Overexpressed in Prostate Cancer
Clark, E. L., Coulson, A., Dalgliesh, C., Rajan, P., Nicol, S. M., Fleming, S., Heer, R., Gaughan, L., Leung, H. Y., Elliott, D. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0932 · Cited by 201 · see citing works
Role of SRC-1 in the Promotion of Prostate Cancer Cell Growth and Tumor Progression
Agoulnik, I. U., Vaid, A., Bingman, W. E., Erdeme, H., Frolov, A., Smith, C. S., Ayala, G., Ittmann, M., & Weigel, N. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3541 · Cited by 201 · see citing works
BAG-1L Protein Enhances Androgen Receptor Function
Froesch, B. A., Takayama, S.-I. J., & Reed, J. C. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.19.11660 · Cited by 197 · see citing works
Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate Cancer
Shiota, M., Bishop, J. L., Nip, K. M., Zardan, A., Takeuchi, A., Cordonnier, T., Beraldi, E., Bazov, J., Fazli, L., Chi, K., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3979 · Cited by 195 · see citing works
SMAD3 represses androgen receptor-mediated transcription.
Hayes, S. A., Zarnegar, M. A., Sharma, M., Yang, F., Peehl, D. M., ten Dijke, P., & Sun, Z. (2001) · PubMed · Cited by 192 · see citing works
STAT3 mediates IL‐6‐induced neuroendocrine differentiation in prostate cancer cells
Spiotto, M., & Chung, T. (2000) · The Prostate · doi:10.1002/(sici)1097-0045(20000215)42:3 · Cited by 191 · see citing works
Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer
Gnanapragasam, V. J., Leung, H. Y., Pulimood, A., Neal, D. E., & Robson, C. N. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2179 · Cited by 189 · see citing works
Suppression Versus Induction of Androgen Receptor Functions by the Phosphatidylinositol 3-Kinase/Akt Pathway in Prostate Cancer LNCaP Cells with Different Passage Numbers
Lin, H., Hu, Y., Yang, L., Altuwaijri, S., Chen, Y.-T., Kang, H., & Chang, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300676200 · Cited by 187 · see citing works
Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells
Krongrad, A., Wilson, C. M., Wilson, J. D., et al. (1991) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(91)90262-q · Cited by 186 · see citing works
A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
Heath, E. I., Hillman, D. W., Vaishampayan, U. N., Sheng, S., Sarkar, F. H., Harper, F. W. K., Gaskins, M., Pitot, H. C., Tan, W. W., Ivy, S. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0221 · Cited by 186 · see citing works
MicroRNA let-7c Suppresses Androgen Receptor Expression and Activity via Regulation of Myc Expression in Prostate Cancer Cells
Nadiminty, N., Tummala, R., Lou, W., Zhu, Y., Zhang, J., Chen, X., White, R. D., Kung, H., Evans, C. P., & Gao, A. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.278705 · Cited by 184 · see citing works
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
Molife, L. R., Attard, G., Fong, P. C. C., Karavasilis, V., Reid, A. H. M., Patterson, S. G., Riggs, C. E., Higano, C. S., Stadler, W. M., McCulloch, W. F., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp270 · Cited by 184 · see citing works
The nuclear factor-κB pathway controls the progression of prostate cancer to androgen-independent growth.
Jin, R. J., Lho, Y., Connelly, L., Wang, Y., Yu, X., Saint Jean, L., Case, T. C., Ellwood-Yen, K., Sawyers, C. L., Bhowmick, N. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0107 · Cited by 182 · see citing works
Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer
Welsbie, D. S., Xu, J., Chen, Y., Borsu, L. A., Scher, H. I., Rosen, N. X., & Sawyers, C. L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2216 · Cited by 182 · see citing works
Antiandrogen Bicalutamide Promotes Tumor Growth in a Novel Androgen-Dependent Prostate Cancer Xenograft Model Derived from a Bicalutamide-Treated Patient
Yoshida, T., Kinoshita, H., Segawa, T., Nakamura, E., Inoue, T., Shimizu, Y., Kamoto, T., & Ogawa, O. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0817 · Cited by 178 · see citing works
Identification of a Cellular Receptor for Transforming Growth Factor-β in Rat Ventral Prostate and Its Negative Regulation by Androgens*
Kyprianou, N., & Isaacs, J. T. (1988) · Endocrinology · doi:10.1210/endo-123-4-2124 · Cited by 177 · see citing works
Targeting Continued Androgen Receptor Signaling in Prostate Cancer
Massard, C., & Fizazi, K. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2815 · Cited by 177 · see citing works
Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes.
Lu, S., Tsai, S. Y., & Tsai, M. (1997) · PubMed · Cited by 176 · see citing works
Epigenetic Repression of miR-31 Disrupts Androgen Receptor Homeostasis and Contributes to Prostate Cancer Progression
Lin, P., Chiu, Y., Banerjee, S., Park, K., Mosquera, J. M., Γιαννοπούλου, Ε., Alves, P., Tewari, A. K., Gerstein, M., Beltran, H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2968 · Cited by 168 · see citing works
Androgens Modulate Expression of Transcription Intermediary Factor 2, an Androgen Receptor Coactivator whose Expression Level Correlates with Early Biochemical Recurrence in Prostate Cancer
Agoulnik, I. U., Vaid, A., Nakka, M., Alvarado, M., Bingman, W. E., Erdem, H., Frolov, A., Smith, C. S., Ayala, G. E., Ittmann, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1023 · Cited by 168 · see citing works
Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor
Heisler, L. E., Evangelou, A. I., Lew, A. M., Trachtenberg, J., Elsholtz, H. P., & Brown, T. J. (1997) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(96)03970-6 · Cited by 167 · see citing works
Androgen regulation of micro‐RNAs in prostate cancer
Waltering, K. K., Porkka, K. P., Jalava, S. E., Urbanucci, A., Kohonen, P. J., Latonen, L., Kallioniemi, O., Jenster, G. W., & Visakorpi, T. (2010) · The Prostate · doi:10.1002/pros.21276 · Cited by 166 · see citing works
Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells
Gross, M. E., Liu, B., Tan, J.-A., French, F. S., Carey, M., & Shuai, K. (2001) · Oncogene · doi:10.1038/sj.onc.1204489 · Cited by 165 · see citing works
MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer
Rokhlin, O. W., Scheinker, V., Taghiyev, A. F., Bumcrot, D. A., Glover, R. A., & Cohen, M. B. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.8.6284 · Cited by 159 · see citing works
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.
Malinowska, K., Neuwirt, H., Cavarretta, I. T., Bektic, J., Steiner, H., Dietrich, H., Moser, P. L., Fuchs, D., Hobisch, A., & Culig, Z. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0174 · Cited by 157 · see citing works
Self-citation
FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells
Ni, L., Yang, C.-S., Gioeli, D., Frierson, H., Toft, D. O., & Paschal, B. M. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01891-08 · Cited by 155 · cited 1× · see citing works
“A cochaperone of Hsp90, FK506-binding protein, augments AR activity in LAPC4 cells [94].”
Background
Characterisation of a Tip60 Specific Inhibitor, NU9056, in Prostate Cancer
Coffey, K., Blackburn, T. J., Cook, S., Golding, B. T., Griffin, R. J., Hardcastle, I. R., Hewitt, L., Huberman, K. H., McNeill, H. V., Newell, D. R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045539 · Cited by 154 · see citing works
Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides
Eder, I. E., Čulig, Z., Ramoner, R. E., Thurnher, M., Putz, T., Nessler‐Menardi, C., Tiefenthaler, M., Bartsch, G. H., & Klocker, H. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700202 · Cited by 152 · see citing works
Δ 5 -Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells
Miyamoto, H., Yeh, S., Lardy, H. A., Messing, E. M., & Chang, C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11083 · Cited by 147 · see citing works
Inhibition of Interleukin-6 with CNTO328, an Anti-Interleukin-6 Monoclonal Antibody, Inhibits Conversion of Androgen-Dependent Prostate Cancer to an Androgen-Independent Phenotype in Orchiectomized Mice
Wallner, L. P., Dai, J., Escara-Wilke, J. F., Zhang, J., Yao, Z., Lü, Y., Trikha, M., Nemeth, J. A., Zaki, M. H., & Keller, E. T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3447 · Cited by 144 · see citing works
Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
Seaton, A., Scullin, P., Maxwell, P. J., Wilson, C., Pettigrew, J., Gallagher, R., O'Sullivan, J. M., Johnston, P. G., & Waugh, D. J. J. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn109 · Cited by 143 · see citing works
FOXA1 Promotes Tumor Progression in Prostate Cancer and Represents a Novel Hallmark of Castration-Resistant Prostate Cancer
Gerhardt, J., Montani, M., Wild, P. J., Beer, M., Huber, F., Hermanns, T., Müntener, M., & Kristiansen, G. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.10.021 · Cited by 141 · see citing works
Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models
Denmeade, S. R., Sokoll, L. J., Dalrymple, S. L., Rosen, D. M., Gady, A. M., Bruzek, D. J., Ricklis, R. M., & Isaacs, J. T. (2003) · The Prostate · doi:10.1002/pros.10199 · Cited by 136 · see citing works
Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
Vasaitis, T. S., Belosay, A., Schayowitz, A., Khandelwal, A., Chopra, P., Gediya, L. K., Guo, Z., Fang, H., Njar, V. C. O., & Brodie, A. M. H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0230 · Cited by 134 · see citing works
Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
Kaku, T., Hitaka, T., Ojida, A., Matsunaga, N., Adachi, M., Tanaka, T., Hara, T., Yamaoka, M., Kusaka, M., Okuda, T., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.08.066 · Cited by 127 · see citing works
miR 488* inhibits androgen receptor expression in prostate carcinoma cells
Sikand, K., Slaibi, J. E., Singh, R., Slane, S. D., & Shukla, G. C. (2010) · International Journal of Cancer · doi:10.1002/ijc.25753 · Cited by 124 · see citing works
Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP
Zhu, W. (2001) · Carcinogenesis · doi:10.1093/carcin/22.9.1399 · Cited by 124 · see citing works
Roles of microRNAs during prostatic tumorigenesis and tumor progression
Fang, Y.-X., & Gao, W.-Q. (2013) · Oncogene · doi:10.1038/onc.2013.54 · Cited by 123 · see citing works
Small Molecule Inhibition of the Steroid Receptor Coactivators, SRC-3 and SRC-1
Wang, Y., Lonard, D. M., Yu, Y., Chow, D., Palzkill, T. G., & O’Malley, B. W. (2011) · Molecular Endocrinology · doi:10.1210/me.2011-1222 · Cited by 121 · see citing works
1α,25-Dihydroxyvitamin D3 Actions in LNCaP Human Prostate Cancer Cells Are Androgen-Dependent*
Zhao, X., Ly, L. H., Peehl, D. M., et al. (1997) · Endocrinology · doi:10.1210/endo.138.8.5328 · Cited by 121 · see citing works
Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells
Santer, F. R., Malinowska, K., Čulig, Z., & Cavarretta, I. T. R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0200 · Cited by 119 · see citing works
Self-citation
Steroid Receptor Coactivator-3 and Activator Protein-1 Coordinately Regulate the Transcription of Components of the Insulin-Like Growth Factor/AKT Signaling Pathway
Yan, J., Yu, C., Özen, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2442 · Cited by 118 · see citing works
Anti‐interleukin‐6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice
Smith, P. C., & Keller, E. T. (2001) · The Prostate · doi:10.1002/pros.1080 · Cited by 117 · see citing works
Androgen Receptor and Invasion in Prostate Cancer
Hara, T., Miyazaki, H., Lee, A., Tran, C. P., & Reiter, R. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1929 · Cited by 117 · see citing works
Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator.
Nishimura, K., Ting, H., Harada, Y., Tokizane, T., Nonomura, N., Kang, H., Chang, H., Yeh, S., Miyamoto, H., Shin, M., et al. (2003) · PubMed · Cited by 115 · see citing works
Androgen Stimulates Matrix Metalloproteinase-2 Expression in Human Prostate Cancer
Liao, X., Thrasher, J. B., Pelling, J. C., Holzbeierlein, J. M., Sang, Q. A., & Li, B. (2003) · Endocrinology · doi:10.1210/en.2002-0157 · Cited by 114 · see citing works
Increased smad expression and activation are associated with apoptosis in normal and malignant prostate after castration.
Brodin, G., ten Dijke, P., Funa, K., Heldin, C., & Landström, M. (1999) · PubMed · Cited by 114 · see citing works
The anti‐interleukin‐6 antibody siltuximab down‐regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study
Karkera, J. D., Steiner, H., Li, W., Skradski, V., Moser, P. L., Riethdorf, S., Reddy, M. P., Puchalski, T. A., Safer, K., Prabhakar, U., et al. (2011) · The Prostate · doi:10.1002/pros.21362 · Cited by 113 · see citing works
Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
Yamaoka, M., Hara, T., Hitaka, T., Kaku, T., Takeuchi, T., Takahashi, J., Asahi, S., Miki, H., Tasaka, A., & Kusaka, M. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.01.001 · Cited by 113 · see citing works
TWO MUTATIONS IDENTIFIED IN THE ANDROGEN RECEPTOR OF THE NEW HUMAN PROSTATE CANCER CELL LINE MDA PCA 2A
Zhao, X.-Y., BOYLE, B., Krishnan, A. V., Navone, N. M., Peehl, D. M., & Feldman, D. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68158-x · Cited by 110 · see citing works
The androgen receptor co‐activator CBP is up‐regulated following androgen withdrawal and is highly expressed in advanced prostate cancer
Comuzzi, B., Nemes, C., Schmidt, S. U., Jasarevic, Z., Lodde, M., Pycha, A., Bartsch, G. H., Offner, F. A., Čulig, Z., & Hobisch, A. (2004) · The Journal of Pathology · doi:10.1002/path.1609 · Cited by 109 · see citing works
Retinoblastoma and p16 proteins in mammary carcinoma: Their relationship to cyclin D1 and histopathological parameters
Dublin, E. A., Patel, N. K., Gillett, C., Smith, P., Peters, G. G., & Barnes, D. M. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980220)79:1 · Cited by 109 · see citing works
Androgen Receptor Expression in Prostate Carcinoma Cells Suppresses α6β4 Integrin-Mediated Invasive Phenotype1
Bonaccorsi, L., Carloni, V., Muratori, M., Salvadori, A., Giannini, A., Carini, M., Serio, M., Forti, G., & Baldi, E. (2000) · Endocrinology · doi:10.1210/endo.141.9.7640 · Cited by 107 · see citing works
Androgen Deprivation Increases p300 Expression in Prostate Cancer Cells
Heemers, H. V., Sebo, T. J., Debes, J. D., Regan, K. M., Raclaw, K. A., Murphy, L. M., Hobisch, A., Čulig, Z., & Tindall, D. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2836 · Cited by 107 · see citing works
Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
Liu, Y., Karaca, M., Zhang, Z., Gioeli, D., Earp, H. S., & Whang, Y. E. (2010) · Oncogene · doi:10.1038/onc.2010.103 · Cited by 106 · see citing works
Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival
Wang, Y., Михайлова, М. А., Bose, S., Pan, C.-X., White, R. D., & Ghosh, P. (2008) · Oncogene · doi:10.1038/onc.2008.318 · Cited by 104 · see citing works
Androgen Receptor Alterations in Prostate Cancer Relapsed during a Combined Androgen Blockade by Orchiectomy and Bicalutamide
Haapala, K., HYYTINEN, E.-R., Roiha, M., et al. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780378 · Cited by 104 · see citing works
Androgen-Induced Cell Migration: Role of Androgen Receptor/Filamin A Association
Castoria, G., D’Amato, L., Ciociola, A., Giovannelli, P., Giraldi, T., Sepe, L., Paolella, G., Barone, M. V., Migliaccio, A., & Auricchio, F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017218 · Cited by 102 · see citing works
Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells.
Asim, M., Siddiqui, I. A., Hafeez, B. B., Baniahmad, A., & Mukhtar, H. (2008) · Oncogene · doi:10.1038/sj.onc.1211016 · Cited by 101 · see citing works
Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus
Shiota, M., Yokomizo, A., Masubuchi, D., Tada, Y., Inokuchi, J., Eto, M., Uchiumi, T., Fujimoto, N., & Naito, S. (2009) · The Prostate · doi:10.1002/pros.21088 · Cited by 101 · see citing works
Interleukin-6 Regulates Androgen Synthesis in Prostate Cancer Cells
Chun, J. Y., Nadiminty, N., Dutt, S. S., Lou, W., Yang, J. C., Kung, H., Evans, C. P., & Gao, A. C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0640 · Cited by 101 · see citing works
p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6.
Debes, J. D., Comuzzi, B., Schmidt, L. J., Dehm, S. M., Culig, Z., & Tindall, D. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2837 · Cited by 92 · see citing works
Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity.
Mahajan, K., Challa, S., Coppola, D., Lawrence, H., Luo, Y., Gevariya, H., Zhu, W., Chen, Y. A., Lawrence, N. J., & Mahajan, N. P. (2010) · The Prostate · doi:10.1002/pros.21163 · Cited by 86 · see citing works
Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival
Sun, C., Shi, Y., Xu, L., Nageswararao, C., Davis, L., Segawa, T., Dobi, A. L., McLeod, D. G. R., & Srivastava, S. K. (2006) · Oncogene · doi:10.1038/sj.onc.1209424 · Cited by 86 · see citing works
Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness.
Kashat, M. A., Azzouz, L., Sarkar, S., Kong, D., Li, Y., & Sarkar, F. H. (2012) · Europe PMC (PubMed Central) · Cited by 83 · see citing works
Androgen Induction of Prostate Cancer Cell Invasion Is Mediated by Ezrin
Chuan, Y.-C., Pang, S., Cedazo-Mı́nguez, Á., Norstedt, G., Pousette, Å., & Flores‐Morales, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602237200 · Cited by 82 · see citing works
PIAS1 Is Increased in Human Prostate Cancer and Enhances Proliferation through Inhibition of p21
Hoefer, J., Schäfer, G., Klocker, H., Erb, H. H. H., Mills, I. G., Hengst, L., Puhr, M., & Čulig, Z. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.01.026 · Cited by 82 · see citing works
Vav3 Oncogene Is Overexpressed and Regulates Cell Growth and Androgen Receptor Activity in Human Prostate Cancer
Dong, Z., Liu, Y., Lu, S., Wang, A. Y., Lee, K., Wang, L., Revelo, M. P., & Lu, S. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0048 · Cited by 82 · see citing works
Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells
Wang, G., Jones, S. J. M., Marra, M. A., & Sadar, M. D. (2006) · Oncogene · doi:10.1038/sj.onc.1209715 · Cited by 81 · see citing works
A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells
Wang, Y., Kreisberg, J. I., Bedolla, R. G., Михайлова, М. А., White, R. D., & Ghosh, P. (2007) · Oncogene · doi:10.1038/sj.onc.1210435 · Cited by 81 · see citing works
FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells
Cornforth, A. N., Davis, J. S., Khanifar, E., Nastiuk, K. L., & Krolewski, J. J. (2008) · Oncogene · doi:10.1038/onc.2008.80 · Cited by 77 · see citing works
Molecular Endocrinology
(1994) · Elsevier eBooks · doi:10.1016/c2009-0-02383-6 · Cited by 77 · see citing works
The Transcriptional Co-Activator cAMP Response Element-Binding Protein-Binding Protein Is Expressed in Prostate Cancer and Enhances Androgen- and Anti-Androgen-Induced Androgen Receptor Function
Comuzzi, B., Lambrinidis, L., Rogatsch, H., Godoy‐Tundidor, S., Knežević, N., Krhen, I., Mareković, Z., Bartsch, G. H., Klocker, H., Hobisch, A., et al. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63814-x · Cited by 76 · see citing works
Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer
Oh, W. K., Galsky, M. D., Stadler, W. M., et al. (2011) · Urology · doi:10.1016/j.urology.2011.04.041 · Cited by 76 · see citing works
Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
Sadar, M. D., & Gleave, M. E. (2000) · PubMed · Cited by 74 · see citing works
Pattern of Somatic Androgen Receptor Gene Mutations in Patients with Hormone-Refractory Prostate Cancer
HYYTINEN, E.-R., Haapala, K., Thompson, J. S., et al. (2002) · Laboratory Investigation · doi:10.1097/01.lab.0000038924.67707.75 · Cited by 74 · see citing works
Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway
Lee, S. O., Lou, W., Hou, M., Oñate, S. A., & Gao, A. C. (2003) · Oncogene · doi:10.1038/sj.onc.1206735 · Cited by 71 · see citing works
The effect of environmental cues on the differentiation of myofibroblasts in peritoneal granulation tissue
(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70 · see citing works
A Splicing Variant of the Androgen Receptor Detected in a Metastatic Prostate Cancer Exhibits Exclusively Cytoplasmic Actions
Jagla, M., Fève, M., Kessler, P., et al. (2007) · Endocrinology · doi:10.1210/en.2007-0446 · Cited by 67 · see citing works
Mechanisms of Cell Death Induced by Histone Deacetylase Inhibitors in Androgen Receptor–Positive Prostate Cancer Cells
Rokhlin, O. W., Glover, R. B., Guseva, N. V., Taghiyev, A. F., Kohlgraf, K. G., & Cohen, M. B. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0085 · Cited by 66 · see citing works
Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
Wang, L. G., Ossowski, L., & Ferrari, A. C. (2001) · PubMed · Cited by 66 · see citing works
Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2
Feng, S., Tang, Q., Sun, M., Chun, J. Y., Evans, C. P., & Gao, A. C. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0823 · Cited by 65 · see citing works
ART-27, an Androgen Receptor Coactivator Regulated in Prostate Development and Cancer
Taneja, S. S., Ha, S., Swenson, N. K., Pineda‐Torra, I., Rome, S., Walden, P. D., Huang, H. Y., Shapiro, E., Garabedian, M. J., & Logan, S. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306576200 · Cited by 63 · see citing works
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
He, S.-Q., Zhang, C.-H., Shafi, A., Sequeira, M., Acquaviva, J., Friedland, J. C., Sang, J., Smith, D. L., Weigel, N., Wada, Y., et al. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1698 · Cited by 61 · see citing works
Inappropriate Activation of the Androgen Receptor by Nonsteroids: Involvement of the Src Kinase Pathway and Its Therapeutic Implications
Desai, S. J., Ma, A., Tepper, C. G., Chen, H.-W., & Kung, H.-J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2582 · Cited by 61 · see citing works
Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells
Attardi, B., Burgenson, J., Hild, S. A., & Reel, J. R. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2004.04.013 · Cited by 60 · see citing works
Androgen receptor levels are upregulated by Akt in prostate cancer
Ha, S., Ruoff, R., Kahoud, N., Franke, T. F., & Logan, S. K. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0204 · Cited by 60 · see citing works
Androgen Receptor Splice Variants are Resistant to Inhibitors of Hsp90 and FKBP52, which alter Androgen Receptor Activity and Expression
Shafi, A., Cox, M., & Weigel, N. (2013) · Steroids · doi:10.1016/j.steroids.2012.12.013 · Cited by 57 · see citing works
Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
Attar, R. M., Jure‐Kunkel, M., Balog, A., Cvijic, M. E., Dell-John, J., Rizzo, C. A., Schweizer, L., Spires, T. E., Platero, J. S., Obermeier, M. T., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1111 · Cited by 57 · see citing works
The activity of the androgen receptor variant AR‐V7 is regulated by FOXO1 in a PTEN‐PI3K‐AKT‐dependent way
Mediwala, S. N., Sun, H., Szafran, A. T., Hartig, S. M., Sonpavde, G., Hayes, T. G., Thiagarajan, P., Mancini, M. A., & Marcelli, M. (2012) · The Prostate · doi:10.1002/pros.22566 · Cited by 54 · see citing works
Targeted Overexpression of Vav3 Oncogene in Prostatic Epithelium Induces Nonbacterial Prostatitis and Prostate Cancer
Liu, Y., Mo, J. Q., Hu, Q., Boivin, G. P., Levin, L., Lu, S., Yang, D., Dong, Z., & Lu, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0645 · Cited by 45 · see citing works
Stimulation of Prostate Cancer Cellular Proliferation and Invasion by the Androgen Receptor Co-Activator ARA70β
Peng, Y., Li, C. X., Chen, F., Wang, Z., Ligr, M., Melamed, J., Wei, J., Gerald, W. L., Pagano, M., Garabedian, M. J., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070065 · Cited by 45 · see citing works
Leupaxin, a Novel Coactivator of the Androgen Receptor, Is Expressed in Prostate Cancer and Plays a Role in Adhesion and Invasion of Prostate Carcinoma Cells
Kaulfuß, S., Grzmil, M., Hemmerlein, B., Thelen, P., Schweyer, S., Neesen, J., Bubendorf, L., Glass, A. G., Jarry, H., Auber, B., et al. (2008) · Molecular Endocrinology · doi:10.1210/me.2006-0546 · Cited by 44 · see citing works
Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer
Rathkopf, D. E., Liu, G., Carducci, M. A., Eisenberger, M. A., Anand, A., Morris, M. J., Slovin, S. F., Sasaki, Y., Takahashi, S., Ozono, S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2955 · Cited by 43 · see citing works
PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
Gravina, G., Marampon, F., Muzi, P., Mancini, A., Piccolella, M., Negri-Cesi, P., Motta, M., Lenzi, A., Cesare, E. D., Tombolini, V., et al. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-12-0240 · Cited by 43 · see citing works
The Steroid Receptor Coactivator-3 Is Required for the Development of Castration-Resistant Prostate Cancer
Tien, J. C.-Y., Liu, Z., Liao, L., Wang, F., Xu, Y., Wu, Y., Zhou, N., Ittmann, M., & Xu, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3929 · Cited by 42 · see citing works
Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells
Chou, Y.-W., Chaturvedi, N. K., Ouyang, S., Lin, F., Kaushik, D., Wang, J., Kim, I., & Lin, M. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.07.015 · Cited by 40 · see citing works
Direct peripheral conversion of dehydroepiandrosterone to testosterone glucuronoside
Korenman, S. G., & Lipsett, M. B. (1965) · Steroids · doi:10.1016/0039-128x(65)90120-0 · Cited by 35 · see citing works
Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation—A new paradigm for cooperation among prostate tumor cells
Lapouge, G., Erdmann, É., Marcias, G., Jagla, M., Monge, A., Kessler, P., Serra, S., Lang, H., Didier Jacqmin, D., Bergerat, J., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22830 · Cited by 32 · see citing works
Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats
Hara, T., Kouno, J., Kaku, T., Takeuchi, T., Kusaka, M., Tasaka, A., & Yamaoka, M. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.10.020 · Cited by 31 · see citing works
Oligomeric proanthocyanidin complexes (OPC) exert anti‐proliferative and pro‐apoptotic effects on prostate cancer cells
Neuwirt, H., Arias, M. C., Puhr, M., et al. (2008) · The Prostate · doi:10.1002/pros.20829 · Cited by 29 · see citing works
Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells
Iacopino, F., Urbano, R., Graziani, G., Muzi, A., Pierluigi, N., & Sica, G. (1992) · International Journal of Oncology · doi:10.3892/ijo_32_6_1293 · Cited by 26 · see citing works
Androgen receptor primes prostate cancer cells to apoptosis through down-regulation of basal p21 expression
Lin, Y.-T., Lu, Z., Kokontis, J. M., & Xiang, J. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.10.135 · Cited by 18 · see citing works
Untitled work
Sánchez (2002) · doi:10.1379/1466-1268(2002)007

Flagged first, then by citations

Sorted by citations

Ecdysone and Mediator Change Energy Metabolism to Terminate Proliferation in Drosophila Neural Stem Cells
Homem, C. C. F., Steinmann, V., Burkard, T. R., Jais, A., Esterbauer, H., & Knoblich, J. A. (2014) · Cell · doi:10.1016/j.cell.2014.06.024 · Cited by 243 · see citing works
Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer
Li, H., Melnyk, J. E., Fu, B. X. H., Shrestha, R., Zhang, M., Sjöström, M., Feng, S., Anderson, J. A., Han, W., Chesner, L. N., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02388-8 · Cited by 10 · see citing works
Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer
Huang, M., Chen, L., Ma, X., & Xu, H. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03542-8 · Cited by 9 · see citing works
“This diversity can be attributed to multiple factors, including dysregulated transcription in AR and PI3K signaling pathways, as well as defects in DNA repair mechanisms, all of which contribute significantly to the initiation and progression of PCa [34, 37, 38].”
Background

[The mechanisms of prostate cancer progression through androgen receptor].
Goto, Y., Sakamoto, S., & Ichikawa, T. (2016) · PubMed
Homologous Androgen Receptor Up-Regulation in Osteoblastic Cells May Be Associated with Enhanced Functional Androgen Responsiveness
Wiren, K. M., Keenan, E. J., Zhang, X., Ramsey, B., & ORWOLL, E. S. (1999) · Endocrinology · doi:10.1210/endo.140.7.6753 · Cited by 34 · see citing works
Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review
Anantharaman, A., & Friedlander, T. W. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.11.003 · Cited by 23 · see citing works
Androgen Receptor Rediscovered: The New Biology and Targeting the Androgen Receptor Therapeutically
Ryan, C. J., & Tindall, D. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2005 · Cited by 244 · see citing works
Abstract 4554: Regulation of intracrine androgen synthesis by NF-kappaB2/p52
Nadiminty, N., Tummala, R., Chun, J. Y., et al. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-4554

Authors: Culig, Z., & Santer, F. R.
Venue: Cancer and Metastasis Reviews
Publisher: Springer Science and Business Media LLC
Published: 2014-01-03
Volume: 33
Issue: 2-3
Pages: 413-427
ISSN: 0167-7659 (ISSN-L)
1573-7233
DOI: 10.1007/s10555-013-9474-0
OpenAlex: W2072403982
Semantic Scholar: 65f5ee21d5031f38f94e0586500e507e954ca712
Cited by: 283
References: 173
Citations by year: 2026: 16 · 2025: 21 · 2024: 32 · 2023: 51 · 2022: 45 · 2021: 35 · 2020: 24 · 2019: 22 · 2018: 12 · 2017: 10 · 2016: 7 · 2015: 6 · 2014: 2
FWCI: 1.43
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Cancer and Metastasis Reviews (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
Keywords: androgen receptor, prostate cancer, androgen receptor signaling, androgen receptor mutations, microRNA, androgen receptor coactivator, androgen deprivation therapy, chemoprevention, androgen synthesis inhibition, nuclear translocation, tumor progression
MeSH terms: Animals, Humans, Ligands, Male, Mutation, Prostatic Neoplasms, Receptors, Androgen, Transcription Factors, Transcription, Genetic, Signal Transduction, Gene Expression Regulation, Neoplastic, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Androgen receptor signaling in prostate cancer

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks